Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2022
<sup>177</sup>Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate CancerThorsten Derlin, Liam Widjaja, Rudolf A Werner, et al.
Cancers|July 2, 2021
PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand TherapyLiam Widjaja, Rudolf A Werner, Tobias L Ross, et al.
The Prostate|October 11, 2021
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapyLiam Widjaja, Thorsten Derlin, Tobias L Ross, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 27, 2021
Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapyLiam Widjaja, Rudolf A Werner, Tobias L Ross, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 22, 2022
Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapyLiam Widjaja, Rudolf A Werner, Elke Krischke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2025
<sup>99m</sup>Tc-MIP-1404 SPECT/CT Companion Diagnostic for <sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate CancerThorsten Derlin, Liam Widjaja, Nina Natascha Harke, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 25, 2026
Metformin and renal dosimetry in patients undergoing [<sup>177</sup>Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetrySophie Carina Siegmund, Astrid Delker, Liam Widjaja, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2026
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [<sup>225</sup>Ac]Ac/[<sup>177</sup>Lu]Lu-PSMA-therapyGabriel T Sheikh, Sophie C Siegmund, Liam Widjaja, et al.
Molecular Imaging and Biology|September 30, 2025
Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid CarcinomaSophie Carina Kunte, Vera U Wenter, Adrien Holzgreve, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [<sup>177</sup>Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA DynamicsLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
Pageof 2